Oppenheimer Raises Price Target for BridgeBio Oncology Therapeutics
Oppenheimer has raised its price target for BridgeBio Oncology Therapeutics to $22, maintaining a 'buy' rating, a 195.90% upside from the current price.
Key Points
- Oppenheimer raised its price target for BridgeBio Oncology Therapeutics, Inc. (BBOT) to $22, affirming a 'buy' rating on June 22, 2026.
- Oppenheimer's $22 price target implies 195.90% upside from BridgeBio Oncology Therapeutics, Inc.'s ($BBOT) current $7.43 share price.
- Shares of BBOT traded near $7.89 on Tuesday, with a market cap of about $630.4 million and a beta of 0.287.
- Eventide Asset Management and others opened new positions in BBOT, and analysts have a strong buy consensus with a mean target price of $25.11.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Oppenheimer has raised its price target for BridgeBio Oncology Therapeutics, Inc. (NasdaqGM:BBOT) to $22, maintaining a 'buy' rating. This update came from analyst Mazahir Alimohamed on June 22, 2026, as the firm continues to see potential in the biotechnology company's future.
Oppenheimer vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in BridgeBio Oncology Therapeutics
Several institutional investors have shown interest in BridgeBio Oncology Therapeutics. Eventide Asset Management, LLC opened a new position with 541,181 shares valued at approximately $4.7 million. Avidity Partners Management LP also initiated a stake with 43,853 shares worth about $392,484. Accent Capital Management, LLC and Barclays PLC joined in, opening new positions with 335 and 212 shares, valued at $2,998 and $1,897, respectively.
BridgeBio Oncology Therapeutics, Inc. Stock Down 14.9%
Shares of BridgeBio Oncology Therapeutics traded near $7.89 on Tuesday. The company, with a market cap of about $630.4 million, is in the biotechnology sector. It has a beta of 0.287, indicating lower volatility compared to the market. The stock has seen a 52-week low of $7.00 and a high of $14.87, with moving averages at $8.41 for 50 days and $10.55 for 200 days. The firm's financial health appears strong with a current ratio of 6.16 and a quick ratio of 5.835.
$BBOT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 22, 2026, Oppenheimer assumed coverage with a 'buy' rating and a $22 price target. Other analysts have similarly positive views, with Canaccord Genuity initiating coverage on May 11, 2026, with a 'buy' rating and a $23 target. HC Wainwright & Co. maintained a 'buy' rating with a $29 target on March 6, 2026. Overall, the stock has a strong buy consensus, with a mean target price of $25.11 across nine analyst opinions.
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California. It focuses on developing small-molecule therapeutics for treating various cancers, including non-small cell lung cancer and breast cancer. The company is led by CEO Dr. Pedro J. Beltran and employs 106 people. It is actively involved in clinical trials for its pipeline of innovative oncology treatments.
Bottom Line
Oppenheimer's new price target for BridgeBio Oncology Therapeutics underscores the firm's confidence in the company's potential. Investors often track such analyst ratings closely as they provide insights into a stock's future prospects. However, it's important to remember that these ratings are based on past and current data and may not reflect future market conditions.
Get BridgeBio Oncology Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BBOT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.